Livagen 20mg

Livagen is a tetrapeptide (Lys-Glu-Asp-Pro) from the Khavinson bioregulatory series targeting hepatic tissue. The liver is arguably the organ where tissue-specific gene regulation matters most — hepatocyte function encompasses drug metabolism, protein synthesis, lipid metabolism, and insulinotropic signalling pathways in vitro, all governed by a set of liver-specific transcription factors (HNF1, HNF4, FOXA family) that define hepatic identity. Livagen research asks whether short peptide bioregulation can influence that transcriptional program in aging or stressed liver tissue.

The Khavinson mechanism proposed for Livagen follows the series pattern: the peptide is proposed to enter hepatocytes, reach the nucleus, and interact with promoter sequences governing liver-specific gene expression. Published research examines albumin synthesis rates, cytochrome P450 expression patterns, and age-related changes in hepatic protein production. Most published work originates from the Saint Petersburg Institute of Bioregulation and Gerontology. Independent replication is limited, though some external work on short peptide effects in hepatic models exists.

Research Applications

Hepatocyte homeostasis and liver aging models are the primary applications. Hepatic protein synthesis and enzyme expression research, particularly around age-related changes in CYP450 patterns, is the secondary focus. For researchers working with metabolic disease models, Livagen's hepatic targeting overlaps interestingly with the hepatic endpoints studied in GLP-1/glucagon dual agonist research — a potentially complementary mechanistic angle.

Specifications

Storage: Lyophilized: −20°C, away from light. Once reconstituted: 2–8°C, use within 4 weeks.

Quality: HPLC purity analysis, mass spec identity confirmation, endotoxin testing on every batch. COA ships with every order. EU-based QC under CERTALAB S.R.L.

For research purposes only. Not for human consumption.